The design of drugs for HIV and HCV.
Since the discovery of the human immunodeficiency virus (HIV) in 1983, dramatic progress has been made in the development of novel antiviral drugs. The HIV epidemic fuelled the development of new antiviral drug classes, which are now combined to provide highly active antiretroviral therapies. The need for the treatment of hepatitis C virus (HCV), which was discovered in 1989, has also provided considerable impetus for the development of new classes of antiviral drugs, and future treatment strategies for chronic HCV might involve combination regimens that are analogous to those currently used for HIV. By considering the drug targets in the different stages of the life cycle of these two viruses, this article presents aspects of the history, medicinal chemistry and mechanisms of action of approved and investigational drugs for HIV and HCV, and highlights general lessons learned from anti-HIV-drug design that could be applied to HCV.
Rega Institute for Medical Research, K. U. Leuven, B-3000 Leuven, Belgium.
Erik
E
De Clercq
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D015195:Drug Design; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans
D019380:Anti-HIV Agents; D000998:Antiviral Agents